KR20240023095A - Vegf 및 ang2에 결합하는 이중특이적 결합 분자 및 이의 사용 - Google Patents
Vegf 및 ang2에 결합하는 이중특이적 결합 분자 및 이의 사용 Download PDFInfo
- Publication number
- KR20240023095A KR20240023095A KR1020247000079A KR20247000079A KR20240023095A KR 20240023095 A KR20240023095 A KR 20240023095A KR 1020247000079 A KR1020247000079 A KR 1020247000079A KR 20247000079 A KR20247000079 A KR 20247000079A KR 20240023095 A KR20240023095 A KR 20240023095A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- gly
- amino acid
- seq
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110623779.2 | 2021-06-04 | ||
| CN202110623779 | 2021-06-04 | ||
| PCT/CN2022/096848 WO2022253314A1 (zh) | 2021-06-04 | 2022-06-02 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240023095A true KR20240023095A (ko) | 2024-02-20 |
Family
ID=84323888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247000079A Pending KR20240023095A (ko) | 2021-06-04 | 2022-06-02 | Vegf 및 ang2에 결합하는 이중특이적 결합 분자 및 이의 사용 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240247057A1 (https=) |
| EP (1) | EP4349861A4 (https=) |
| JP (1) | JP2024520693A (https=) |
| KR (1) | KR20240023095A (https=) |
| CN (1) | CN117500828A (https=) |
| AU (1) | AU2022287100A1 (https=) |
| CA (1) | CA3221192A1 (https=) |
| IL (1) | IL309035A (https=) |
| MX (1) | MX2023014407A (https=) |
| TW (1) | TW202302633A (https=) |
| WO (1) | WO2022253314A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3231417A1 (en) * | 2021-09-10 | 2023-03-16 | Jian Shi | Anti-ang2 antibody, preparation method therefor, and application thereof |
| IL321122A (en) * | 2022-12-01 | 2025-07-01 | Innovent Biologics Suzhou Co Ltd | Formulations containing dual-specific binding molecules that bind VEGF and ANG2 and their uses |
| WO2025151018A1 (ko) * | 2024-01-12 | 2025-07-17 | 주식회사 노벨티노빌리티 | C-kit 및 vegf에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| WO2025228314A1 (en) * | 2024-04-29 | 2025-11-06 | Shenzhen Oculgen Biomedical Technology Co., Ltd | Ang2/vegf bispecific binding molecules |
| WO2026037352A1 (zh) * | 2024-08-13 | 2026-02-19 | 长春金赛药业有限责任公司 | 同时结合VEGF及Ang-2的Fc融合蛋白及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| SG11201408538PA (en) | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| WO2016073157A1 (en) * | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
| BR112017009764A2 (pt) * | 2014-11-10 | 2018-02-20 | Hoffmann La Roche | anticorpos biespecíficos e métodos de uso em oftalmologia |
| MA49279A (fr) * | 2017-03-22 | 2020-02-05 | Hoffmann La Roche | Compositions d'anticorps optimisées pour le traitement de troubles oculaires |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
-
2022
- 2022-06-02 IL IL309035A patent/IL309035A/en unknown
- 2022-06-02 MX MX2023014407A patent/MX2023014407A/es unknown
- 2022-06-02 JP JP2023574547A patent/JP2024520693A/ja active Pending
- 2022-06-02 CA CA3221192A patent/CA3221192A1/en active Pending
- 2022-06-02 TW TW111120663A patent/TW202302633A/zh unknown
- 2022-06-02 KR KR1020247000079A patent/KR20240023095A/ko active Pending
- 2022-06-02 WO PCT/CN2022/096848 patent/WO2022253314A1/zh not_active Ceased
- 2022-06-02 AU AU2022287100A patent/AU2022287100A1/en active Pending
- 2022-06-02 US US18/566,197 patent/US20240247057A1/en active Pending
- 2022-06-02 EP EP22815354.0A patent/EP4349861A4/en active Pending
- 2022-06-02 CN CN202280039743.2A patent/CN117500828A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117500828A (zh) | 2024-02-02 |
| US20240247057A1 (en) | 2024-07-25 |
| EP4349861A1 (en) | 2024-04-10 |
| IL309035A (en) | 2024-02-01 |
| AU2022287100A1 (en) | 2024-01-25 |
| MX2023014407A (es) | 2024-04-23 |
| WO2022253314A1 (zh) | 2022-12-08 |
| CA3221192A1 (en) | 2022-12-08 |
| EP4349861A4 (en) | 2025-07-23 |
| TW202302633A (zh) | 2023-01-16 |
| JP2024520693A (ja) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102662387B1 (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| KR20240023095A (ko) | Vegf 및 ang2에 결합하는 이중특이적 결합 분자 및 이의 사용 | |
| US20220235123A1 (en) | Synthetic antibodies against vegf and their uses | |
| WO2022068810A1 (zh) | 抗Claudin18.2和CD3的双特异性抗体以及其用途 | |
| JP2024518724A (ja) | 抗masp2抗体、その抗原結合断片および医薬用途 | |
| IL318511A (en) | Non-neutralizing anti-adrenomedullin antibody, method for its preparation and use | |
| US20200071392A1 (en) | Methods of treating cancer using bifunctional molecules that target growth factors | |
| KR20250139273A (ko) | 삼중특이적 융합 단백질 및 이의 용도 | |
| US20250002570A1 (en) | Anti-vegf a and vegf c bispecific antibodies and use thereof | |
| EP4628097A1 (en) | Preparation containing bispecific binding molecule binding to vegf and ang2 and use thereof | |
| US12422441B2 (en) | Antibodies that bind to natively folded myocilin | |
| KR20230004659A (ko) | 항-인간 신경 성장 인자 항체 | |
| JP7804295B2 (ja) | 二機能性融合タンパク質およびその用途 | |
| HK40104627A (zh) | 双功能融合蛋白及其用途 | |
| CN116478288A (zh) | 红细胞弱结合型人源化cd47抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240102 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250528 Comment text: Request for Examination of Application |